Catalyst Pharmaceuticals, INC Form 4 insider transactions

Patrick J. McEnany, Chairman of the Board and a 10% owner of Catalyst Pharmaceuticals, Inc., reported the sale of 200,000 shares of common stock for personal reasons, not due to any disagreement with the company.

Richard J. Daly, President and CEO of Catalyst Pharmaceuticals, Inc., reported the sale of 70,000 shares of common stock on May 30, 2025, citing personal reasons.

Gary Ingenito, Chief Medical & Regulatory Officer of Catalyst Pharmaceuticals, sold shares of common stock on the open market for personal reasons.

Gary Ingenito, Chief Medical & Regulatory Officer of Catalyst Pharmaceuticals, sold shares on the open market for personal reasons.

Brian Elsbernd, Chief Compliance/Legal Officer of Catalyst Pharmaceuticals, reports the acquisition and disposal of common stock and derivative securities.

Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, sold 30,423 shares of common stock at $22.89 per share on March 3, 2025, for personal reasons.

Richard Daly, CEO of Catalyst Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.

Director David S. Tierney acquired 4,000 shares of Catalyst Pharmaceuticals common stock on February 14, 2025, through the vesting of restricted stock units.

Director Donald A. Denkhaus of Catalyst Pharmaceuticals exercised stock options, acquiring 4,000 shares of common stock on February 14, 2025.

Steve Miller, Chief Operating and Scientific Officer of Catalyst Pharmaceuticals, reports the vesting and delivery of restricted stock units, resulting in an increase in his holdings of common stock.

Director Molly Harper reports the vesting and delivery of restricted stock units resulting in the acquisition and disposal of Catalyst Pharmaceuticals common stock.

Gary Ingenito, Chief Medical & Regulatory Officer of Catalyst Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.

Chief Commercial Officer Jeffrey Del Carmen reports the vesting of restricted stock units and subsequent tax withholding.

Preethi Sundaram, Chief Strategy Officer at Catalyst Pharmaceuticals, reports the vesting and subsequent tax withholding related to restricted stock units.

Director Charles B. O'Keeffe reports the vesting and delivery of restricted stock units into common stock of Catalyst Pharmaceuticals.

Brian Elsbernd, Chief Compliance/Legal Officer of Catalyst Pharmaceuticals, reports the vesting and subsequent tax withholding related to restricted stock units.

Director Donald A. Denkhaus exercised options to purchase 50,000 shares of Catalyst Pharmaceuticals common stock at $2.24 per share.

Michael Kalb, Executive Vice President & CFO of Catalyst Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.

Richard Daly, CEO of Catalyst Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.

Steve Miller, Chief Operating and Scientific Officer of Catalyst Pharmaceuticals, exercised stock options and received 14,000 shares of common stock on December 27, 2024.

Director Charles B. O'Keeffe reports the vesting of restricted stock units in Catalyst Pharmaceuticals, resulting in the acquisition of 1,333 shares.

Director David S. Tierney acquired 1,333 shares of Catalyst Pharmaceuticals common stock on December 27, 2024, through the vesting of restricted stock units.

Gary Ingenito, Chief Medical & Regulatory Officer of Catalyst Pharmaceuticals, reports the vesting of restricted stock units and associated tax withholding.

Richard Daly, CEO of Catalyst Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.

Brian Elsbernd, Chief Compliance/Legal Officer of Catalyst Pharmaceuticals, exercised restricted stock units and disposed of shares to cover withholding taxes on December 27, 2024.

Director Donald A. Denkhaus reports the vesting of restricted stock units into Catalyst Pharmaceuticals common stock.

Chief Commercial Officer Jeffrey Del Carmen reports the vesting of restricted stock units and subsequent tax withholding.

Director Molly Harper reports vesting of restricted stock units in Catalyst Pharmaceuticals, resulting in the acquisition of 1,333 shares.

Preethi Sundaram, Chief Strategy Officer of Catalyst Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.

Steve Miller, Chief Operating and Scientific Officer of Catalyst Pharmaceuticals, exercised stock options for 235,000 shares at $4.01 per share.